Elevance Health, Inc. $ELV Shares Sold by Mcdonald Capital Investors Inc. CA

Mcdonald Capital Investors Inc. CA decreased its stake in Elevance Health, Inc. (NYSE:ELV) by 32.1% in the 3rd quarter, Holdings Channel reports. The firm owned 9,608 shares of the company’s stock after selling 4,541 shares during the quarter. Elevance Health accounts for approximately 0.2% of Mcdonald Capital Investors Inc. CA’s portfolio, making the stock its 18th biggest position. Mcdonald Capital Investors Inc. CA’s holdings in Elevance Health were worth $3,105,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ELV. Physician Wealth Advisors Inc. increased its holdings in Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management grew its holdings in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. Rossby Financial LCC grew its holdings in shares of Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC increased its stake in Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares in the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new position in Elevance Health during the second quarter worth $32,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Elevance Health stock opened at $342.95 on Monday. The stock has a market capitalization of $75.69 billion, a P/E ratio of 13.65, a P/E/G ratio of 1.90 and a beta of 0.50. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The firm’s 50-day moving average is $352.37 and its two-hundred day moving average is $334.71.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the prior year, the firm posted $3.84 earnings per share. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is 27.23%.

Analysts Set New Price Targets

A number of analysts have commented on ELV shares. Barclays decreased their target price on Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Morgan Stanley cut their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.